IMCD Boosts Pharma Portfolio with Trichem India Acquisition

IMCD, world leader in specialty chemicals and formulation and distribution of ingredients, has acquired 100 percent of Trichem's equity, an Indian supplier of pharmaceuticals based in Mumbai. The acquisition enhances IMCD's coverage in India and the Middle East and expands its portfolio in the life sciences business, specifically in active pharmaceutical ingredients (APIs).

Established in 1998, Trichem offers high-quality APIs, pharma intermediates, and formulation solutions. Besides that, the company offers regulatory services to companies active in India's heavily regulated pharmaceutical drug market. Trichem has its operations in India and the Middle East region and posted revenue of approximately INR 1.7 billion (about  Euro 18 million) on a FY annual revenue basis as of March 31, 2025, of which approximately 33 percent was commission-based revenue.

Speaking on the acquisition, Narendra Varde, IMCD India Managing Director, stated, "Considering that India is a top generic player in the global market, acquiring Trichem further consolidates our API strengths and repositions us in the region's life sciences business. We are delighted to have Trichem's seasoned team, whose deep local market knowledge will be an excellent value addition to IMCD."

Also Read: Karnataka Govt Unveils 3-Year Plan to Strengthen Advanced Healthcare Access

Trichem's founder and promoter, Chetan Jain, was optimistic about the transaction, saying, "IMCD and Trichem share a similar vision and entrepreneurial spirit. Trichem has established a proud tradition spanning more than 27 years. With the IMCD global footprint and our existing principal relationships, I am confident that we will build significant value for all stakeholders."

The agreement is part of IMCD's expansion strategy to increase its specialty pharma portfolio in rapidly growing markets.